Jon Kenniston
YOU?
Author Swipe
View article: Corrigendum: A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema
Corrigendum: A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema Open
[This corrects the article DOI: 10.3389/falgy.2024.1436855.].
View article: A phase 1/2 safety and efficacy study of TAK‐754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials
A phase 1/2 safety and efficacy study of TAK‐754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials Open
Introduction Haemophilia A is an X‐linked bleeding disorder resulting from a deficiency of factor VIII (FVIII). To date, multiple gene therapies have entered clinical trials with the goal of providing durable haemostatic protection from a …
View article: Identification of small molecule agonists of fetal hemoglobin expression for the treatment of sickle cell disease
Identification of small molecule agonists of fetal hemoglobin expression for the treatment of sickle cell disease Open
Induction of fetal hemoglobin (HbF) has been shown to be a viable therapeutic approach to treating sickle cell disease and potentially other β-hemoglobinopathies. To identify targets and target-modulating small molecules that enhance HbF e…
View article: A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema
A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema Open
Background Cleaved high-molecular-weight kininogen (HKa) is a disease state biomarker of kallikrein-kinin system (KKS) activation in patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH), the endogenous inhibitor o…
View article: Identification of small molecule agonists of fetal hemoglobin expression for the treatment of sickle cell disease
Identification of small molecule agonists of fetal hemoglobin expression for the treatment of sickle cell disease Open
Induction of fetal hemoglobin (HbF) has been shown to be a viable therapeutic approach to treating sickle cell disease and potentially other β-hemoglobinopathies. To identify targets and target-modulating small molecules that enhance HbF e…
View article: Anti–sFlt-1 Therapy Preserves Lung Alveolar and Vascular Growth in Antenatal Models of Bronchopulmonary Dysplasia
Anti–sFlt-1 Therapy Preserves Lung Alveolar and Vascular Growth in Antenatal Models of Bronchopulmonary Dysplasia Open
Rationale: Pregnancies complicated by antenatal stress, including preeclampsia (PE) and chorioamnionitis (CA), increase the risk for bronchopulmonary dysplasia (BPD) in preterm infants, but biologic mechanisms linking prenatal factors with…
View article: Author Index
Author Index Open
View article: Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody
Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody Open
The neonatal Fc receptor FcRn plays a critical role in the trafficking of IgGs across tissue barriers and in retaining high circulating concentrations of both IgG and albumin. Although generally beneficial from an immunological perspective…
View article: Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis
Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis Open
In this small trial, administration of lanadelumab to patients with hereditary angioedema with C1 inhibitor deficiency reduced cleavage of high-molecular-weight kininogen and attacks of angioedema. (Funded by Dyax; ClinicalTrials.gov numbe…